Glyphosate

CAS No. 1071-83-6

Glyphosate( Atila | Folusen | Lancer )

Catalog No. M27176 CAS No. 1071-83-6

Glyphosate is an herbicide. It also is a possible carcinogen to humans.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 35 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Glyphosate
  • Note
    Research use only, not for human use.
  • Brief Description
    Glyphosate is an herbicide. It also is a possible carcinogen to humans.
  • Description
    Glyphosate is an herbicide. It also is a possible carcinogen to humans.(In Vitro):Glyphosate exposure interferes with mouse oocyte maturation by generating oxidative stress and early apoptosis. Glyphosate induces early apoptosis and autophagy in mouse oocytes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Atila | Folusen | Lancer
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    GPR120
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1071-83-6
  • Formula Weight
    169.073
  • Molecular Formula
    C3H8NO5P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 13.89 mg/mL (82.16 mM)
  • SMILES
    OC(=O)CNCP(O)(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Oh DY, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014 Aug;20(8):942-7.
molnova catalog
related products
  • RA-9

    RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity.

  • Pamrevlumab

    Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).

  • TD52

    TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter.